Metabolic Signatures of Performance in Elite World Tour Professional Male Cyclists.

"Declarations FundingResearch reported in this publication was funded by the National Institute of General and Medical Sciences (RM1GM131968 to ADA), and R01HL146442 (ADA), R01HL149714 (ADA), R01HL148151 (ADA), R01HL161004 (ADA), and R21HL150032 (ADA) from the National Heart, Lung, and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Conflict of interestTravis Nemkov, Kirk C. Hansen, and Angelo D’Alessandro are co-founders of Omix Technologies, Inc. Travis Nemkov, Angelo D’Alessandro, and Iñigo San-Millán are co-founders of Altis Biosciences. Angelo D’Alessandro is a SAB member or consultant for Hemanext Inc, Macopharma, and Forma Therapeutics Inc. Francesca Cendali, Davide Stefanoni, Janel L. Martinez have no conflicts of interests that are directly relevant to the content of this article. Ethics approvalAll study procedures were conducted in accordance with the Declaration of Helsinki and in accordance with a predefined protocol that was approved by the Colorado Multiple Institutional Review Board (COMIRB 17-1281). Consent to participateWritten informed consent was obtained from all subjects. Consent for publicationWhile identifying information is intentionally omitted from this article to maintain anonymity, all subjects provided written informed consent for publication. Availability of data and materialAll data generated as part of this study are presented in the supplementary materials. Code availabilityNo code was generated as part of this study. Author contributionsISM, TN, and AD designed the studies. JLM and ISM performed exercise tests and collected the samples in laboratory and field settings. TN, FC, DS, KCH, and AD performed omics analyses. TN performed data analyses and prepared figures. TN wrote the first version of the manuscript, which was finalized with AD and reviewed and approved by all co-authors. Conflict of interest Travis Nemkov, Kirk C. Hansen, and Angelo D’Alessandro are co-founders of Omix Technologies, Inc. Travis Nemkov, Angelo D’Alessandro, and Iñigo San-Millán are co-founders of Altis Biosciences. Angelo D’Alessandro is a SAB member or consultant for Hemanext Inc, Macopharma, and Forma Therapeutics Inc. Francesca Cendali, Davide Stefanoni, Janel L. Martinez have no conflicts of interests that are directly relevant to the content of this article."

"Funding Research reported in this publication was funded by the National Institute of General and Medical Sciences (RM1GM131968 to ADA), and R01HL146442 (ADA), R01HL149714 (ADA), R01HL148151 (ADA), R01HL161004 (ADA), and R21HL150032 (ADA) from the National Heart, Lung, and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health."